RegulatoryJun 26, 2026, 05:16 PM
Matinas BioPharma Receives NYSE Non-Compliance Notice, Plan Accepted
AI Summary
Matinas BioPharma Holdings, Inc. announced it received a notice from NYSE American for non-compliance with continued listing standards, specifically regarding stockholders' equity falling below required thresholds of $4.0 million and $6.0 million, and sustained losses over five fiscal years. As of March 31, 2026, stockholders' equity was $3.02 million. However, NYSE American has accepted the Company's plan to regain compliance and granted a plan period through October 2, 2027, allowing its shares to continue trading during this time.
Key Highlights
- Matinas BioPharma received a NYSE American notice on June 24, 2026, for non-compliance.
- Non-compliance with Section 1003(a)(ii) due to stockholders' equity below $4.0 million.
- Stockholders' equity was $3.02 million as of March 31, 2026.
- Non-compliance with Section 1003(a)(iii) due to stockholders' equity below $6.0 million.
- Stockholders' equity was $4.83 million as of December 31, 2025.
- Company reported losses in its five most recent fiscal years.
- NYSE American accepted the Company's plan to regain compliance.
- Granted a plan period until October 2, 2027, to achieve compliance.
Price Impact
More from MTNB